Instituto de Investigación Nutricional (IIN), Lima, Peru.
Hospital Modular EsSalud Cutervo, Red Prestacional de Lambayeque, Cajamarca, Peru.
Eur J Pediatr. 2024 Sep;183(9):3705-3718. doi: 10.1007/s00431-024-05679-0. Epub 2024 Jul 8.
Green banana Musa paradisiaca (GB) has been traditionally used to aid in the treatment of diarrhea. This systematic review and meta-analysis aimed to evaluate current evidence of the effect of GB consumption as a complement to standard treatment in the population with acute or persistent diarrhea. We searched PubMed, Scopus, Web of Science, and LILACS from inception to January 2024; there was no language restriction. Only randomized controlled trials using GB as an intervention were included, and studies using antidiarrheal medication were excluded. A meta-analysis was performed to compare the effect of GB on the resolution of acute and persistent diarrhea. To measure the certainty of evidence, the GRADE assessment was used. Nine randomized controlled trials (seven open and two blinded) were included. Studies were conducted in the pediatric population comprising a total of 3996 patients aged 8 to 34 months, eight studies were written in English and one in Spanish. GB-based food consumption significantly increased the hazard of resolution of diarrhea compared to standard treatment (HR 1.96, 95% CI [1.62; 2.37], p < 0.01; I = 52%). The subgroup analysis showed a higher hazard of resolution of diarrhea for children with persistent diarrhea (HR 2.34, 95% CI [1.78; 3.08] compared to acute diarrhea (HR 1.74, 95% CI [1.45; 2.09]).Conclusions: The use of green banana-based foods as a complement to standard treatment in children is probably associated with a faster resolution in acute diarrhea and may aid in the treatment of persistent diarrhea. More clinical trials are necessary to assess if a synergistic effect between GB and other foods exists and proves to be better than GB alone. These findings need to be confirmed in diverse socioeconomic contexts, within the adult population, and under varying health conditionsTrial registration: CRD42024499992.
绿皮芭蕉（Musa paradisiaca）常用于辅助治疗腹泻。本系统评价和荟萃分析旨在评估当前关于绿皮芭蕉作为急性或持续性腹泻人群标准治疗补充的消费效果的证据。我们检索了 PubMed、Scopus、Web of Science 和 LILACS 自成立以来至 2024 年 1 月的文献，没有语言限制。仅纳入使用绿皮芭蕉作为干预措施的随机对照试验，排除使用抗腹泻药物的研究。采用荟萃分析比较了绿皮芭蕉对急性和持续性腹泻缓解的效果。使用 GRADE 评估来衡量证据的确定性。纳入了 9 项随机对照试验（7 项开放性和 2 项双盲）。这些研究均在儿科人群中开展，共有 3996 名 8 至 34 月龄的患者，其中 8 项研究为英文，1 项为西班牙语。与标准治疗相比，基于绿皮芭蕉的食物消费显著增加了腹泻缓解的风险（HR 1.96，95%CI [1.62; 2.37]，p<0.01；I=52%）。亚组分析显示，持续性腹泻儿童的腹泻缓解风险更高（HR 2.34，95%CI [1.78; 3.08]，而急性腹泻的 HR 为 1.74，95%CI [1.45; 2.09]）。结论：在儿童中，将绿皮芭蕉食物作为标准治疗的补充可能与更快缓解急性腹泻相关，并可能有助于治疗持续性腹泻。需要更多的临床试验来评估绿皮芭蕉与其他食物是否存在协同作用，并证明其优于单独使用绿皮芭蕉。这些发现需要在不同的社会经济背景下，在成年人群中，并在不同的健康状况下得到证实。试验注册：CRD42024499992。
